Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats

Won Seok Bang1, Ye Ran Hwang1, Zhengri Li1, Inchul Lee2, Hee Eun Kang1

1College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea.
2Department of Diagnostic Pathology, College of Medicine, University of Ulsan, Asan Foundation, Asan Medical Center, Seoul, South Korea.

Abstract


Purpose: Preliminary study results have shown that rats with non-alcoholic fatty liver disease (NAFLD) induced by 1% orotic acid-containing diet have decreased hepatic CYP2D activity. This study aims to evaluate the possible pharmacokinetic changes in NAFLD as a result of reduced metabolic activity of CYP2D. Methods: The pharmacokinetics of metoprolol and its metabolites, O-desmethyl metoprolol (DMM) and α-hydroxy metoprolol (HM), was investigated in NAFLD and control rats following intravenous (1 mg/kg) and oral (2 mg/kg) administration of metoprolol. The hepatic CYP2D expression was also investigated. Results: NAFLD rats had lower CYP2D expression (by 36.6%) and slower intrinsic clearance (CLint) of metoprolol and formation of HM (by 40.1% and 37.2%, respectively). There were no significant changes in the pharmacokinetics of metoprolol and its metabolites following intravenous administration. In contrast, oral administration of metoprolol resulted in significantly increased total area under plasma concentration-time curve (AUC) of metoprolol (by 127%) and decreased metabolite formation ratios (AUCDMM/AUCMetoprolol [by 42.8%], AUCHM/AUCMetoprolol [by 35.0%]) in NAFLD rats. Moreover, these changes were well correlated with severity of steatosis as quantified by hepatic triglyceride contents. Conclusions: NALFD can lead to a reduction in the hepatic CLint of a drug if it is a substrate of the CYP2D subfamily. The decreased clearance may result in elevated drug concentrations and increased exposure.

J Pharm Pharm Sci, 22 (1): 98-111, 2019

Full Text:

PDF

References


Wang YM, Hu XQ, Xue Y, Li ZJ, Yanagita T, Xue CH. Study on possible mechanism of orotic acid-induced fatty liver in rats. Nutrition 2011; 27: 571-575.

Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007; 17: 1457-1463.

Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-450.

Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta, F, Spanish Collaborative Study Group on Therapeutic Management of Liver Diseases. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol 2003; 59: 71-76.

Su GM, Sefton RM, Murray M. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. J Pharmacol Exp Ther 1999; 291: 953-959.

Cho SJ, Kim SB, Cho HJ, Chong S, Chung SJ, Kang IM, et al. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. J Agric Food Chem 2016; 64: 5598-5606.

Li P, Robertson TA, Thorling CA, Zhang Q, Fletcher LM, Crawford DH, et al. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Drug Metab Dispos 2011; 39: 571-579.

Starkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 2003 ;39: 538-546.

Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-133.

Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009; 37: 2087-2094.

Jung EJ, Kwon SW, Jung BH, Oh SH, Lee BH. Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. J Lipid Res 2011; 52: 1617-1625.

Dostalek M, Hadasova E, Hanesova M, Pistovcakova J, Sulcova A, Jurica J, et al. Effect of methamphetamine on the pharmacokinetics of dextromethorphan and midazolam in rats. Eur J Drug Metab Pharmacokinet 2005; 30: 195-201.

Venhorst J, ter Laak AM, Commandeur JN, Funae Y, Hiroi T, Vermeulen NP. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. J Med Chem 2003; 46: 74-86.

Ha HR, Follath F. Metabolism of antiarrhythmics. Curr Drug Metab 2004; 5: 543-571.

Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726.

Lennard MS, Chapter 25. -Adrenoceptor antagonists. In: Levy, R.H., Thummel, K.E., Trager, W.F., Hansten, P.D., Eichelbaum, M. (Eds.), Metabolite Drug Interaction. Philadelphia: Lippincott Williams & Wilkins, A Wolters Kluwer Company, 2000; p. 348.

Han SY, Yoon I, Chin YW, Cho IW, Lee MG, Choi YH. Pharmacokinetic interaction between metoprolol and SP-8203 in rats: competitive inhibition for the metabolism of metoprolol by SP-8203 via hepatic CYP2D subfamily. Xenobiotica 2012; 42: 1017-1027.

Lee YS, Kim YW, Kim SG, Lee I, Lee MG, Kang HE. Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase. Eur Neuropsychopharmacol 2012; 22: 431-440.

Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112: 608-618.

Lee JH, Lee MG. Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 2008; 25: 1915-1924.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.

Lee U, Lee I, Lee BK, Kang HE. Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats. Eur J Pharm Sci 2013; 50: 447-53.

Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 1995; 249: 61-90.

Yoon IS, Choi MK, Kim JS, Shim CK, Chung SJ, Kim DD. Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 2011; 41: 243-251.

Di Verniero CA, Silberman EA, Mayer MA, Opezzo JA, Taira CA, Hocht C. In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 2008; 51: 532-541.

Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.

Gibaldi M, Perrier D, Pharmacokinetics, second ed. New York: Marcel-Dekker, 1982.

Mitruka BM, Rawnsley HM. Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, second ed. New York: Masson Publishing USA Inc., 1981.

Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.

Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.

Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.

Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10: 447-456.

Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken) 2008; 291: 684-692.

Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121.




DOI: http://dx.doi.org/10.18433/jpps30268